

Supplement S2. List of prohibited therapies during the study period

Platelet preparations (except in patients who received platelet transfusion once prior to percutaneous liver ablation based on the determination of the need for preoperative platelet transfusion and for use as rescue therapy); blood preparations except for platelet preparation, red blood cell preparation, and albumin preparation; anticancer drugs (except for transcatheter hepatic arterial chemoembolization and lipiodolization after completion of assessment on Day 8); interferon preparations; macrophage colony-stimulating factor products; granulocyte colony-stimulating factor products; erythropoietin; TPO receptor agonists; antithrombotics (heparin, aspirin, dipyridamole, ticlopidine, urokinase, among others) except for use as rescue therapy; hemostatic agents except for topical use and for use as rescue therapy; other investigational products; thoracotomy; laparotomy; splenectomy; partial splenic embolization; hepatectomy; liver transplantation; percutaneous ethanol injection therapy; transcatheter arterial infusion (except for lipiodolization); radiotherapy; and endoscopic injection sclerotherapy.